Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 20Observational 3Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

Blood Specimen Collection 15Imatinib Mesylate 10Flow Cytometry 10nilotinib 8Surveys and Questionnaires 8Polymerase Chain Reaction 8ponatinib 6Cytogenetic Analysis 6ruxolitinib 5bosutinib 5Psychiatric Rehabilitation 5Dasatinib 5Therapeutics 4Interviews as Topic 4Biopsy 4asciminib 3Observation 3Microarray Analysis 3In Situ Hybridization, Fluorescence 3Immunoenzyme Techniques 3Amplified Fragment Length Polymorphism Analysis 3olverembatinib 2fludarabine 2Watchful Waiting 2Tyrosine Kinase Inhibitors 2Molecular Diagnostic Techniques 2Influenza Vaccines 2Immunologic Techniques 2Immunohistochemistry 2Hydroxyurea 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × asciminib × Myeloid × Clear all
NCT05943522 2026-04-20

Asciminib RMP Study

Novartis

Recruiting
600 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06092879 2026-02-06

ASSURE-3

Novartis

Active not recruiting
201 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05421091 2024-03-27

Special Drug Use-results Surveillance of Scemblix Tablets

Novartis

Completed
550 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡